Nivolumab

Nivolumab conferred a statistically significant and clinically meaningful improvement in recurrence-free survival vs. placebo among patients with completely resected stage IIB or IIC melanoma, according to the agent’s manufacturer.

An experimental test may help predict which patients with cancer may develop disease recurrence after immunotherapy treatment, according to study results published in Clinical Cancer Research.

The combination of nivolumab and ipilimumab after nephrectomy failed to extend DFS among patients with localized renal cell carcinoma at high risk for relapse, results of the phase 3 CheckMate 914 trial showed.

This year’s European Society for Medical Oncology Congress featured potentially practice-changing research in kidney cancer, cutaneous squamous cell carcinoma, lung cancer and melanoma.

Adjuvant nivolumab extended RFS compared with placebo among patients with stage IIB/stage IIC melanoma, according to topline data released by the agent’s manufacturer.

Two cycles of neoadjuvant nivolumab plus low-dose ipilimumab induced durable pathologic responses among patients with mismatch repair-deficient colon cancer, according to study results presented at ESMO Congress.

Cabozantinib plus nivolumab and ipilimumab conferred a significant PFS benefit vs. nivolumab and ipilimumab alone among patients with advanced renal cell carcinoma, according to results of the COSMIC-313 trial presented at ESMO Congress.

In this video, Andrew Ciupek, PhD, discusses findings from the Alliance trial, IMpower010 and NADIM-2.

Narjust Florez (Duma), MD, discusses results from two studies presented at World Conference on Lung Cancer — IMpower010 and NADIM-2

Hossein Borghaei, DO, MS, spoke with Healio about findings from the S1800A Lung-MAP substudy and CheckMate 816.